119 related articles for article (PubMed ID: 28388355)
1. In Silico Analysis of L1/L2 Sequences of Human Papillomaviruses: Implication for Universal Vaccine Design.
Ghorban Hosseini N; Tebianian M; Farhadi A; Hossein Khani A; Rahimi A; Mortazavi M; Hosseini SY; Taghizadeh M; Rezaei M; Mahdavi M
Viral Immunol; 2017 Apr; 30(3):210-223. PubMed ID: 28388355
[TBL] [Abstract][Full Text] [Related]
2. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
3. In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses.
Kayyal M; Bolhassani A; Noormohammadi Z; Sadeghizadeh M
Mol Biotechnol; 2021 Dec; 63(12):1192-1222. PubMed ID: 34308516
[TBL] [Abstract][Full Text] [Related]
4. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
5. L1 and L2 gene polymorphisms in HPV-58 and HPV-33: implications for vaccine design and diagnosis.
Chen Z; Jing Y; Wen Q; Ding X; Zhang S; Wang T; Zhang Y; Zhang J
Virol J; 2016 Oct; 13(1):167. PubMed ID: 27717385
[TBL] [Abstract][Full Text] [Related]
6. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.
Oumeslakht L; Ababou M; Badaoui B; Qmichou Z
Gene; 2021 May; 782():145533. PubMed ID: 33636291
[TBL] [Abstract][Full Text] [Related]
7. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
[TBL] [Abstract][Full Text] [Related]
8. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
[TBL] [Abstract][Full Text] [Related]
9. A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches.
Negahdaripour M; Eslami M; Nezafat N; Hajighahramani N; Ghoshoon MB; Shoolian E; Dehshahri A; Erfani N; Morowvat MH; Ghasemi Y
Infect Genet Evol; 2017 Oct; 54():402-416. PubMed ID: 28780192
[TBL] [Abstract][Full Text] [Related]
10. Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras.
Pineo CB; Hitzeroth II; Rybicki EP
Plant Biotechnol J; 2013 Oct; 11(8):964-75. PubMed ID: 23924054
[TBL] [Abstract][Full Text] [Related]
11. Protective immunity against Chlamydia trachomatis genital infection induced by a vaccine based on the major outer membrane multi-epitope human papillomavirus major capsid protein L1.
Xu W; Liu J; Gong W; Chen J; Zhu S; Zhang L
Vaccine; 2011 Mar; 29(15):2672-8. PubMed ID: 21324344
[TBL] [Abstract][Full Text] [Related]
12. Mutant canine oral papillomavirus L1 capsid proteins which form virus-like particles but lack native conformational epitopes.
Chen Y; Ghim SJ; Jenson AB; Schlegel R
J Gen Virol; 1998 Sep; 79 ( Pt 9)():2137-46. PubMed ID: 9747722
[TBL] [Abstract][Full Text] [Related]
13. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
[TBL] [Abstract][Full Text] [Related]
14. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.
Zhang T; Liu H; Chen X; Wang Z; Wang S; Qu C; Zhang J; Xu X
Vaccine; 2016 Nov; 34(46):5531-5539. PubMed ID: 27729176
[TBL] [Abstract][Full Text] [Related]
15. Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.
Zhang X; Xin L; Li S; Fang M; Zhang J; Xia N; Zhao Q
Hum Vaccin Immunother; 2015; 11(5):1277-92. PubMed ID: 25751641
[TBL] [Abstract][Full Text] [Related]
16. Combination of human papillomaviruses L1 and L2 multiepitope constructs protects mice against tumor cells.
Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
Fundam Clin Pharmacol; 2021 Dec; 35(6):1055-1068. PubMed ID: 33930201
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of recombinant BPV-1 L1 protein for the production of a bovine papillomavirus VLP vaccine.
Módolo DG; Araldi RP; Mazzuchelli-de-Souza J; Pereira A; Pimenta DC; Zanphorlin LM; Beçak W; Menossi M; de Cassia Stocco R; de Carvalho RF
Vaccine; 2017 Mar; 35(12):1590-1593. PubMed ID: 28222997
[TBL] [Abstract][Full Text] [Related]
18. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
[TBL] [Abstract][Full Text] [Related]
19. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
20. Stop codon mutagenesis for homogenous expression of human papillomavirus L1 protein in Escherichia coli.
Wang D; Fan F; Li Z; Liu X; Song S; Wei S; He M; Lin Y; Li Z; Wei M; Yu H; Gu Y; Li S; Xia N
Protein Expr Purif; 2017 May; 133():110-120. PubMed ID: 28267627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
